Ovarian
small cell carcinoma of hypercalcemic type is a rare
neoplasm that typically occurs in young females. We describe three cases of ovarian
small cell carcinoma of hypercalcemic type occurring in patients aged 24, 37, and 25 years. The first patient had stage IIc disease and had primary surgery with a left
salpingo-oophorectomy and omentectomy, followed by
chemotherapy with
cisplatin and
etoposide. Upon a second relapse, pelvic
lymphadenectomy was performed, followed by
chemotherapy with
docetaxel. She is alive for 4 years without any recurrence after the initial treatment. In vitro drug-sensitivity assay revealed the
tumor cells were sensitive to
taxane and resistant to
irinotecan. The second patient had stage III disease and had primary debulking surgery with bilateral
salpingo-oophorectomy, simple
hysterectomy, omentectomy, low-anterior resection, and
lymphadenectomy, followed by
chemotherapy with
paclitaxel and
carboplatin. Four months after the initial treatment she relapsed and died. The
tumor cells were sensitive to
platinum,
taxane, and
doxorubicin, but resistant to
irinotecan. The third patient had stage III disease and had right
salpingo-oophorectomy, omentectomy, and
lymphadenectomy, followed by
chemotherapy with
cisplatin,
cyclophosphamide, and
doxorubicin. She relapsed 4 months after completing the
chemotherapy and died 5 months after secondary debulking surgery. The
tumor cells were sensitive to
platinum,
taxane, and
doxorubicin, but resistant to
irinotecan. The drug-sensitivity assays suggested that a non-
irinotecan,
taxane-containing combination might have been suitable as first-line
chemotherapy for these patients. However, an effect of such a regimen was seen in only one patient with early-stage disease, and this questions the validity of chemosensitivity testing.